Connect with us

CBD News

Tilray’s Clinical Trial the First Ever Human Study Testing Cannabis’ Efficiency in Treating TIPN

Cheryl Anne

Published

on

Tilray’s Clinical Trial the First Ever Human Study Testing Cannabis’ Efficiency in Treating TIPN
- Ad -

Premium medical cannabis producer, Tilray has recently involved itself in a clinical trial which is set to test the effects of cannabis on treating breast cancer reports Clinical Trials Arena. As per the claims made, the study will be the first ever human testing of its kind, that looks at patients suffering from taxane-induced peripheral neuropathy (TIPN).

Taxane-derived agents are popularly found in chemotherapy drugs used for treating cancer patients. Unfortunately, peripheral neuropathy is deemed one of its adverse effects, which often times is irreversible. In fact, this issue is common across women patients, with at least 67 percent of all cancer patients affected by it. Hence, the need to find a solution for what’s currently used as a solution itself.

The Vice President of Tilray’s Global Patient Research and Access, Philippe Lucas has since shared that Tilray is focused on advancing itself within cannabis research, adding that the firm wishes to contribute to the overall understanding of cannabis benefits.

As for the study, which is expected to last eight weeks, it will be led by Columbia University Irving Medical Center’s psych professor, Diana Martinez and neurobiology professor, Margaret Haney. The method used here is simply dividing the sample into two groups, one receiving a product containing a combination of CBD and THC, while the other will be given a placebo. Haney has since expressed enthusiasm in being part of the cannabis research, noting that:

“There is exciting preclinical evidence showing that THC and CBD significantly reduce TIPN, and our study will be the first to test this in a well-powered clinical trial.”

Cheryl Anne hails from Great Britain and casts a large shadow with her master’s degree in Relationship Therapy as well as a number of other professional accreditations. While she specializes in psychological thrillers and self-help books, her undeniable and uncanny knack for sifting through the cracks of the cannabis and CBD space are extremely necessary and sought after.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.